While in the secondary analysis, the considerably less conservative but clinically meaningful criterion of stable reaction (outlined being a 50% or more reduction in MADRS from baseline for two months) was used. Of the patients who realized secure response, twenty five.eight% inside the esketamine group and fifty seven.6% during the placebo group r